Publication

Video

Supplements and Featured Publications

My Treatment Approach: Locally Advanced Lung Cancer
Volume1
Issue 1

Dr. Costin on Initial Considerations in Early-Stage Lung Cancer

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Dan Costin, MD, co-medical director, White Plains Hospital Center for Cancer Care, director, Cancer and Blood Specialists of New York, discusses initial considerations in early-stage lung cancer.

Patients with early-stage lung cancer typically require a multidisciplinary approach to treatment, says Costin. For example, thoracic surgeons, in addition to medical oncologists, will often be involved in initial treatment decisions.

In the early-stage setting, tissue diagnosis and appropriate staging are needed, says Costin. The majority of patients will undergo a CT-guided biopsy or a navigational bronchoscopy to determine tissue diagnosis. For staging, patients typically undergo a PET scan.

For a patient with a confirmed diagnosis of early-stage lung cancer, initial treatment selection is based on factors such as patient comorbidities, surgical eligibility, and results of molecular testing, concludes Costin.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.